Zobrazeno 1 - 10
of 202
pro vyhledávání: '"Thomas S Lin"'
Autor:
Ajai Chari, Jonathan L. Kaufman, Jacob Laubach, Douglas W. Sborov, Brandi Reeves, Cesar Rodriguez, Rebecca Silbermann, Luciano J. Costa, Larry D. Anderson, Nitya Nathwani, Nina Shah, Naresh Bumma, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M. Wildes, Robert Z. Orlowski, Kenneth H. Shain, Andrew J. Cowan, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S. Lin, Peter M. Voorhees, Saad Z. Usmani, Paul G. Richardson
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract The randomized, phase 2 GRIFFIN study (NCT02874742) evaluated daratumumab plus lenalidomide/bortezomib/dexamethasone (D-RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM). We present final post hoc analyses (median follow-up
Externí odkaz:
https://doaj.org/article/bb6796db0ba84a22b84787f34a884f56
Autor:
Thomas S Lin
Publikováno v:
Pharmacogenomics and Personalized Medicine, Vol 2010, Iss default, Pp 51-59 (2010)
Thomas S LinGlaxoSmithKline Oncology R&D, Collegeville, PA, USAAbstract: Ofatumumab, a novel humanized monoclonal anti-CD20 antibody, was recently approved by the FDA for the treatment of fludarabine and alemtuzumab refractory chronic lymphocytic leu
Externí odkaz:
https://doaj.org/article/fcf15011551e480c8f4fa3680f23977d
Autor:
Natalie S. Callander, Rebecca Silbermann, Jonathan L. Kaufman, Kelly N. Godby, Jacob Laubach, Timothy M. Schmidt, Douglas W. Sborov, Eva Medvedova, Brandi Reeves, Binod Dhakal, Cesar Rodriguez, Saurabh Chhabra, Ajai Chari, Susan Bal, Larry D. Anderson, Bhagirathbhai R. Dholaria, Nitya Nathwani, Parameswaran Hari, Nina Shah, Naresh Bumma, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M. Wildes, Robert Z. Orlowski, Kenneth H. Shain, Andrew J. Cowan, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S. Lin, Smith Giri, Luciano J. Costa, Saad Z. Usmani, Paul G. Richardson, Peter M. Voorhees
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-8 (2024)
Abstract In the MASTER study (NCT03224507), daratumumab+carfilzomib/lenalidomide/dexamethasone (D-KRd) demonstrated promising efficacy in transplant-eligible newly diagnosed multiple myeloma (NDMM). In GRIFFIN (NCT02874742), daratumumab+lenalidomide/
Externí odkaz:
https://doaj.org/article/ebc38d6b2c3c4c4a957f6410c2bc2f56
Autor:
Wenjun Ni, Jia Ji, Zunyan Dai, Audrey Papp, Amy J Johnson, Sunjoo Ahn, Katherine L Farley, Thomas S Lin, James T Dalton, Xiaobai Li, David Jarjoura, John C Byrd, Wolfgang Sadee, Michael R Grever, Mitch A Phelps
Publikováno v:
PLoS ONE, Vol 5, Iss 11, p e13792 (2010)
Flavopiridol is a cyclin-dependent kinase inhibitor in phase II clinical development for treatment of various forms of cancer. When administered with a pharmacokinetically (PK)-directed dosing schedule, flavopiridol exhibited striking activity in pat
Externí odkaz:
https://doaj.org/article/d855ac1e3ffb492e8c542945d869e74a
Autor:
Scott A. Soefje, Corinne Carpenter, Katherine Carlson, Samir Awasthi, Thomas S. Lin, Shuchita Kaila, Daniel Tarjan, Nikhil Kayal, Christian Kirkup, Tyler E. Wagner, Kathleen S. Gray, Shaji Kumar
Publikováno v:
JCO Oncology Practice. 19:e542-e549
PURPOSE: Median duration of daratumumab (DARA) administration for treatment of multiple myeloma is 3-7 hours for the intravenous formulation (DARA IV) and 3-5 minutes for the subcutaneous formulation (DARA SC). Here, we describe clinical administrati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bd74b8a67c536e60c63def529c6f20ca
https://doi.org/10.1200/op.22.00421
https://doi.org/10.1200/op.22.00421
Autor:
Ajay K Nooka, Jonathan L Kaufman, Cesar Rodriguez, Andrzej Jakubowiak, Yvonne Efebera, Brandi Reeves, Tanya Wildes, Sarah A Holstein, Larry D Anderson, Ashraf Badros, Leyla Shune, Ajai Chari, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S Lin, Paul G Richardson, Peter Voorhees
Publikováno v:
Future Oncology. 18:4443-4456
What is this summary about? This is a summary of a publication about Black participants of the GRIFFIN clinical study that was published in Blood Cancer Journal in April 2022. The GRIFFIN clinical study looked at the treatment combination of daratumu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::47dbc0c121be4ca8e423206d901fca66
https://doi.org/10.2217/fon-2022-0775
https://doi.org/10.2217/fon-2022-0775
Autor:
Rebecca Silbermann, Jacob Laubach, Jonathan L. Kaufman, Douglas W. Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Luciano J. Costa, Larry D. Anderson, Nitya Nathwani, Nina Shah, Naresh Bumma, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Robert Z. Orlowski, Kenneth H. Shain, Andrew J. Cowan, Katharine S. Gries, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S. Lin, Paul G. Richardson, Saad Usmani, Peter M. Voorhees
Publikováno v:
Blood. 140:1146-1149
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4d9f779d2a94446644bbafbcc4715c3c
https://doi.org/10.1182/blood-2022-162313
https://doi.org/10.1182/blood-2022-162313
Autor:
Natalie Callander, Rebecca Silbermann, Jonathan L. Kaufman, Kelly N. Godby, Jacob P Laubach, Timothy Martin Schmidt, Douglas W Sborov, Eva Medvedova, Brandi Reeves, Binod Dhakal, Cesar Rodriguez, Saurabh Chhabra, Ajai Chari, Susan Bal, Larry D. Anderson, Bhagirathbhai Dholaria, Nitya Nathwani, Parameswaran Hari, Nina Shah, Naresh Bumma, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M. Wildes, Robert Z. Orlowski, Ken H. Shain, Andrew J. Cowan, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S. Lin, Smith Giri, Luciano J. Costa, Paul G. Richardson, Saad Usmani, Peter M. Voorhees
Publikováno v:
Blood. 140:10144-10147
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1a55ec9a192011f1d71ebcc7c30ccc11
https://doi.org/10.1182/blood-2022-160451
https://doi.org/10.1182/blood-2022-160451
Autor:
Ajai Chari, Jonathan L. Kaufman, Jacob P Laubach, Douglas W Sborov, Brandi Reeves, Cesar Rodriguez, Rebecca Silbermann, Luciano J. Costa, Larry D. Anderson, Nitya Nathwani, Nina Shah, Naresh Bumma, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M. Wildes, Robert Z. Orlowski, Kenneth H. Shain, Andrew J. Cowan, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S. Lin, Paul G. Richardson, Saad Usmani, Peter M. Voorhees
Publikováno v:
Blood. 140:7278-7281
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::03b4d63159c0d33d06e182b431da4090
https://doi.org/10.1182/blood-2022-162339
https://doi.org/10.1182/blood-2022-162339
Autor:
Douglas W. Sborov, Muhamed Baljevic, Brandi Reeves, Jacob Laubach, Yvonne A. Efebera, Cesar Rodriguez, Luciano J. Costa, Ajai Chari, Rebecca Silbermann, Sarah A. Holstein, Larry D. Anderson, Jonathan L. Kaufman, Nina Shah, Huiling Pei, Sharmila Patel, Annelore Cortoos, J. Blake Bartlett, Jessica Vermeulen, Thomas S. Lin, Peter M. Voorhees, Paul G. Richardson
Publikováno v:
British Journal of Haematology. 199:355-365
Patients with multiple myeloma are at increased risk of vascular thromboembolic events (VTEs). This post hoc analysis evaluated VTEs in the randomised phase 2 GRIFFIN study (ClinicalTrials.gov Identifier: NCT02874742) that investigated lenalidomide/b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58be0e7ebb2fc67f31ffbf3f329f8aa1
https://doi.org/10.1111/bjh.18432
https://doi.org/10.1111/bjh.18432